{
    "clinical_study": {
        "@rank": "94297", 
        "brief_summary": {
            "textblock": "This is a randomized double-blinded controlled study comparing aerosolized pentamidine with\n      trimethoprim plus sulfamethoxazole (TMP / PurposeX). The latter drug will be administered\n      intravenously for at least 5 days, then changed to oral administration if warranted by the\n      patient's clinical condition."
        }, 
        "brief_title": "A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Zidovudine as long as such therapy is suspended prior to randomization and not\n             reinstituted until therapy for the acute episode is completed.\n\n        Pneumocystis carinii pneumonia (PCP) in an adult who is HIV positive by ELISA, HIV\n        culture, or p24 antigenemia, or is a member of a risk group for HIV infection (homosexual\n        or bisexual men, intravenous drug abusers, recipients of HIV infected blood products, and\n        the sexual partners of the foregoing groups).\n\n          -  The patient must have a resting Alveolar - arterial oxygen (A-a) DO2 less than 30\n             mmHg on room air at all ACTG sites, except San Francisco General Hospital. Other\n             sites will enter patients up to a resting (A-a) DO2 = or < 55 mmHg on room air.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Zidovudine as long as such therapy is suspended prior to randomization and not\n             reinstituted until therapy for the acute episode is completed.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Dyspnea.\n\n          -  Cough.\n\n          -  Bronchospasm.\n\n          -  History of a major adverse reaction to pentamidine or sulfonamide containing\n             preparations.\n\n        Patients with the following will be excluded:\n\n          -  Inability to cooperate with aerosol administration because of dyspnea, cough,\n             bronchospasm, or other reasons.\n\n          -  History of a major adverse reaction to pentamidine or sulfonamide containing\n             preparations.\n\n          -  In the opinion of the investigator, the patient would not complete therapy or\n             follow-up for social reasons.\n\n        Prior Medication:\n\n        Excluded within 14 days of study entry:\n\n          -  Systemic steroids above adrenal replacement doses.\n\n          -  Excluded within 6 weeks of study entry:\n\n          -  Other antiprotozoal regimen for this episode such as trimethoprim / sulfamethoxazole\n             (TMP / PurposeX).\n\n          -  Pyrimethamine.\n\n          -  Fansidar.\n\n          -  Pentamidine.\n\n          -  Eflornithine (DFMO).\n\n          -  Dapsone, whether therapeutic or prophylactic, or any of these agents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002056", 
            "org_study_id": "023A", 
            "secondary_id": "87-001"
        }, 
        "intervention": {
            "intervention_name": "Pentamidine isethionate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pentamidine", 
                "Trimethoprim", 
                "Trimethoprim-Sulfamethoxazole Combination", 
                "Sulfamethoxazole"
            ]
        }, 
        "keyword": [
            "Trimethoprim-Sulfamethoxazole Combination", 
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Pentamidine", 
            "Injections, Intravenous", 
            "Administration, Oral", 
            "Aerosols", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rosemont", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60018"
                }, 
                "name": "LyphoMed Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Montgomery AB, Edison RE, Sattler F, Hopewell P, Mason G, Feigal DW. Aerosolized pentamidine vs. trimethoprim/sulfamethoxazole for acute Pneumcoystis carinii pneumonia (PCP): a randomized double blind trial. Int Conf AIDS. 1990 Jun 20-23;6(1):220 (abstract no ThB395)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002056"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LyphoMed", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1989"
    }, 
    "geocoordinates": {
        "LyphoMed Inc": "41.989 -87.871"
    }
}